The 81st Annual Meeting of the Japanese Society of Hematology

Presentation information

Print

Oral Session

Oral Session 1-7A Malignant Lymphoma: Clinical Trials

Fri. Oct 11, 2019 9:00 AM - 10:00 AM No.7 (Tokyo International Forum, 5F Hall D5)

Chair: Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

[OS1-7A-4] Phase 1 study of an oral dual PI3K-δ,γ inhibitor, duvelisib, in Japanese patients with R/R lymphoma

Koji Kato1, Koji Izutsu2,3, Hitoshi Kiyoi4 (1.Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan, 2.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 4.Department of Hematology and Oncology, Nagoya University, Nagoya, Japan)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.

Password